MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- University of Zurich
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Confirm that lung density map extraction is feasible through Hyper-Cones & ZTE scanning.
Study Overview
Brief Summary
MRI 3D UTE Hyper-Cones & ZTE for PET/MR lung attenuation correction & for lung diagnostic imaging
Detailed Description
The primary objective is to clinically test the feasibility of 3D UTE Hyper-Cones & ZTE in capturing lung density of patients with lung diseases at reasonable clinical imaging times compared to standard MR lung protocols (LAVA-Flex, PROPELLER). Secondly, we want to investigate if Hyper-Cones & ZTE can be used for lung imaging such as vessels and air-pathways, oncological patients, lung nodules and lung infiltration & parenchyma pathophysiology such as chronic obstructive pulmonary disease.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •informed consent and signature
- •clinical PET/CT planned and performed at Wagi site in Schlieren
- •male or female patients
- •from 18 to 80 years of age.
Exclusion Criteria
- •- same exclusion criteria as for the clinical PET/CT exam (i.e. pregnant women).
- •Additional exclusion criteria:
- •- standard exclusion criteria for clinical MRI (evaluated by clinical standard determined by MRI questionnaire).
Arms & Interventions
PET/MR (single arm)
PET and MR sequence acquisition on SIGNA PET/MR device
Intervention: PET/MR image acquisition (Diagnostic Test)
Outcomes
Primary Outcomes
Confirm that lung density map extraction is feasible through Hyper-Cones & ZTE scanning.
Time Frame: 1 year
Confirm that lung density map extraction is feasible through Hyper-Cones \& ZTE scanning.
Secondary Outcomes
No secondary outcomes reported